RNAi Therapeutics
•24 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (24)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
RNAi therapeutics are part of Lilly's genetic medicine push.
|
$945.23B |
$977.27
-2.26%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
C5 siRNA program represents RNA interference therapeutics in Regeneron’s genetic medicines portfolio.
|
$81.42B |
$746.49
-3.64%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$42.33B |
$317.07
-1.05%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$7.89B |
$55.00
-5.34%
|
|
CRSP
CRISPR Therapeutics AG
SRSD107 is an RNA interference therapeutic, aligning with the RNAi Therapeutics category.
|
$4.76B |
$48.91
-2.05%
|
|
APLS
Apellis Pharmaceuticals, Inc.
APLJ? APL-3007 is an siRNA therapeutic targeting FcRn, placing the program under the RNAi Therapeutics theme.
|
$2.45B |
$18.39
-5.13%
|
|
WVE
Wave Life Sciences Ltd.
WVE-007 includes an siRNA (RNA interference) program, making RNAi therapeutics a core modality for the company.
|
$2.35B |
$13.34
-5.26%
|
|
SRPT
Sarepta Therapeutics, Inc.
siRNA platform (TRiM) with Arrowhead collaboration positions Sarepta in RNA interference therapeutics.
|
$1.79B |
$17.06
-2.93%
|
|
AGIO
Agios Pharmaceuticals, Inc.
AG-236 is an siRNA (RNAi) therapeutic in preclinical development, fitting RNAi therapeutics as a major modality in Agios's pipeline.
|
$1.64B |
$27.61
-1.62%
|
|
VIR
Vir Biotechnology, Inc.
Elebsiran is an RNA interference (RNAi) therapeutic, placing Vir in RNAi Therapeutics.
|
$1.37B |
$9.48
-3.41%
|
|
QURE
uniQure N.V.
miQURE silencing technology enables RNA interference-based therapeutics, placing the company in the RNAi therapeutics modality.
|
$1.09B |
$16.95
-3.47%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$948.91M |
$4.58
-7.58%
|
|
BNTC
Benitec Biopharma Inc.
Benitec's ddRNAi approach centers on RNA interference therapeutics, placing it under RNAi Therapeutics.
|
$410.41M |
$12.14
-1.10%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT's RNA interference modality (RNAi therapeutics) aligns with a gene-silencing oligonucleotide approach described in the program.
|
$398.84M |
$8.46
-0.94%
|
|
SLN
Silence Therapeutics plc
Silence Therapeutics directly develops RNA interference therapeutics (siRNA) as its core product modality.
|
$329.36M |
$6.99
+0.07%
|
|
VYGR
Voyager Therapeutics, Inc.
VY1706 uses siRNA payload delivered via TRACER capsids, mapping to RNAi Therapeutics.
|
$269.66M |
$4.87
+0.41%
|
|
ALEC
Alector, Inc.
ADP064-ABC includes an anti-tau siRNA program, representing RNA interference therapeutics.
|
$243.41M |
$2.24
-3.45%
|
|
RNA
Avidity Biosciences, Inc.
RNA interference (siRNA) payloads are part of the therapeutic approach described (AOC delivering RNA-based payloads).
|
$229.62M |
$14.55
-1.66%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$114.64M |
$1.70
+33.86%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$35.97M |
$5.36
+0.37%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-KIT is described as a precision antisense therapy, aligning with RNAi therapeutics.
|
$13.39M |
$1.00
-3.37%
|
|
RNAZ
TransCode Therapeutics, Inc.
Company focuses on RNA interference (RNAi) therapeutics, including siRNA/miRNA-targeted programs.
|
$7.98M |
$9.65
+0.78%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is based on RNA interference (siRNA), making RNAi therapeutics a core product/framework.
|
$6.53M |
$1.14
+6.07%
|
|
RGBP
Regen BioPharma, Inc.
DiffronC is described as an in vivo siRNA therapy, placing RGBP in the RNAi Therapeutics space.
|
$224038 |
$0.01
|
Loading company comparison...
Loading industry trends...
Loading research report...
